Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01851642 · ClinicalTrials.gov registry record
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
A clinical trial of Alpha-1 Antitrypsin Deficiency and Cystic Fibrosis (CF), sponsored by University of Florida.
- Recruiting
- Registry status
- 220
- Enrollment target
- 1
- Study location
NCT01851642 is a study of Alpha-1 Antitrypsin Deficiency and Cystic Fibrosis (CF) that is actively recruiting participants, run by University of Florida. The registered enrollment target is 220 participants, below the 3,066-participant average among 18 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01851642, a study of Alpha-1 Antitrypsin Deficiency and Cystic Fibrosis (CF), is actively recruiting participants, sponsored by University of Florida.
- RECRUITING
- Registry status
- 220 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to look at how Alpha-1-antitrypsin (AAT) deficiency and Cystic Fibrosis (CF) affect white blood cells in the lungs, called macrophages, and their ability to work.
Conditions Studied
Interventions
- PROCEDURE History and physical exam.
- PROCEDURE Blood draw.
- PROCEDURE Pulmonary function testing.
- DRUG Albuterol inhaler.
Study Locations (1)
Florida
- Shands at the University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2007-08-09 |
| Est. Completion | 2033-07-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01851642
The ClinicalTrials.gov registry entry for NCT01851642 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,066-participant average among 18 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (93% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Alpha-1 Antitrypsin Deficiency appearing as the primary indexed condition, and to 4 interventions - of which History and physical exam. is the first listed.
NCT01851642 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT01851642 about?
NCT01851642 is a clinical study titled "Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs". The purpose of this study is to look at how Alpha-1-antitrypsin (AAT) deficiency and Cystic Fibrosis (CF) affect white blood cells in the lungs, called macrophages, and their ability to work.
What is the current status of trial NCT01851642?
This trial is currently recruiting. The enrollment target is 220 participants. The study started on 2007-08-09. Estimated completion is 2033-07-20.
What conditions does trial NCT01851642 study?
This clinical trial studies the following conditions: Alpha-1 Antitrypsin Deficiency, Cystic Fibrosis (CF), AAT Deficiency, AATD.
What interventions are being tested in trial NCT01851642?
The interventions under investigation include: History and physical exam. (PROCEDURE), Blood draw. (PROCEDURE), Pulmonary function testing. (PROCEDURE), Albuterol inhaler. (DRUG).
Who is sponsoring clinical trial NCT01851642?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01851642 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alpha-1 Antitrypsin Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
RECRUITING
-
PiMZ Longitudinal Cohort (PiMZ Logic)
RECRUITING
-
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
RECRUITING · Phase 2
-
Gene Therapy for Alpha 1- Antitrypsin Deficiency
RECRUITING · Phase 1
-
Alpha-1 Research Registry
RECRUITING
-
A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.